Investigation Report on China's Rosuvastatin Market, 2010-2019

Ever since its marketing, rosuvastatin calcium has become a rising star of the statin class with sales value growing fast. In 2012, it even became the best-selling lipid-lowering drug around the world with a sales value of USD 6.2 billion.

Rosuvastatin develops fast after entering China, annual sales value rising from less than CNY 2 million in 2007 to CNY 672 million in 2014 and CAGR during this period reaching up to 139%. Currently, rosuvastatin in the Chinese market mainly come from the following companies: IPR Pharmaceuticals (US), Lunan Better Pharmaceutical Co., Ltd, Nanjing Chia Tai Tianqing, Simcere and Zhejiang Jingxin Pharmaceutical Co., Ltd, among which IPR Pharmaceuticals (US) has the largest market share of 82.5% for sales value in 2014.

The market size of rosuvastatin is expected to keep growing in the next few years in China.

Key Topics Covered:

1 Related Concepts of Rosuvastatin

2 Market Profile of Rosuvastatin in China

3 Survey on Sales Status of Rosuvastatin in China, 2010-2014

4 Survey on Market Share of Major Manufacturers of Rosuvastatin in China, 2010-2014

5 Survey on Dosage Forms of Rosuvastatin in China, 2010-2014

6 Reference Price of Rosuvastatin in Chinese Hospitals in 2014

7 Major Manufacturers of Rosuvastatin in Chinese Market, 2010-2014

8 Market Outlook of Rosuvastatin in China, 2015-2019

Companies Mentioned

- Lunan Better Pharmaceutical Co., Ltd- Nanjing Chia Tai Tianqing- Nanjing Simcere Dongyuan Pharmaceutical Co., Ltd.- Zhejiang Jingxin Pharmaceutical Co., Ltd- AstraZeneca plc.

For more information visit http://www.researchandmarkets.com/research/ccwrrv/investigation

Media Contact:

Laura Wood, +353-1-481-1716, [email protected]